drugset / Trial / NCT01351636
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.
Timeline
- Start
- 2011-04
- Primary completion
- 2018-10-10
- Completion
- 2018-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arotinolol | Small molecule | 5 mg | — |
| Subject | Arotinolol | Small molecule | 10 mg | — |